Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

20.06 -3.44 (-14.64%)
Streaming Delayed Price Updated: 3:44 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside ↗
Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025. 
Via Benzinga
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
News headline image
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast ↗
 
Via Benzinga
News headline image
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights ↗
 
Via Benzinga
News headline image
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs ↗
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
Via Benzinga
Topics Lawsuit
News headline image
3 Genomics Stocks That May Transform Personalized Medicine ↗
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
News headline image
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
News headline image
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Recap: Ultragenyx Pharmaceutical Q4 Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells ↗
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against... 
Via Benzinga
Topics Lawsuit
News headline image
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 ↗
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March ↗
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Down 1%; Charles Schwab Sales Top Estimates ↗
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study ↗
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. 
Via Benzinga
News headline image
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
News headline image
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.